Latest Headlines

Latest Headlines

Agilent axes 300 employees to focus on applied markets and diagnostics businesses

Agilent Technologies is closing its nuclear magnetic resonance business, as the downsizing of its research products division continues. The move is expected to cost 300 jobs over the next 12 months in Santa Clara, CA, and Yarnton, England. 

St. Jude laying off up to 270 workers in California

The second shift at St. Jude Medical's cardiology device manufacturing facility in Sylmar, a suburb of Los Angeles, is being eliminated, resulting in the loss of up 270 jobs. The layoffs will take effect July 28, reports the San Fernando Valley Business Journal. 

Report: Development IT hit hard in Novartis cutbacks

Over the first few months of 2014, Novartis quietly began laying off workers, shedding an estimated 3,000 jobs in four months. Now BioSpace has provided details of where the ax has fallen and why, with development IT teams suffering heavy job losses.

Report: Abbott is cutting diagnostics division jobs

Abbott laid off an undisclosed number of diagnostics division employees based at its Illinois headquarters, the Chicago Tribune reported recently.

InVivo Therapeutics to ax hydrogel drug delivery program, cutting jobs

InVivo Therapeutics announced June 19 that it is terminating its preclinical hydrogel drug delivery program as the company focuses on its investigational devices for spinal cord injury, the Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells.

Zimmer CEO insists no salespeople will be cut after Biomet merger

Apparently, the $270 million in synergies Zimmer expects to achieve from its $13.4 billion acquisition of Biomet does not include the elimination of any sales reps.

Need a job? J&J, Novartis and Biogen Idec are pharma's favorite employers

With all of the pharma layoffs, lots of folks are looking for a job in the industry. So where are the best places to work? Johnson & Johnson and Novartis if you want to work for a large company. Biogen Idec, Gilead or perhaps Novo Nordisk if you prefer more of a midsize drugmaker.

UPDATED: Pfizer's post-megamerger cost-cutting record? 51,500 jobs in 7 years

In the calm after yesterday's Pfizer-AstraZeneca deal storm, it's time to survey the potential fallout. Pfizer's aggressive strategy for avoiding taxes, totted up by The Wall Street Journal, politely thumped by the Financial Times and skewered by In the Pipeline. Fears for the U.K. science community, articulated by any number of U.K. newspapers.

Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months

Unlike every other Big Pharma company in the world, Novartis tends to prefer to communicate rather selectively when it chops a facility here or winnows out its ranks over there in its global structure.

AstraZeneca adds 550 jobs to the chopping block as profits shrivel

AstraZeneca is cutting an additional 550 jobs from its ranks, bringing the total to 5,600 in an expanded restructuring designed, in part, to give it more money for deals.